Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA

Kailera Therapeutics

Kailera Therapeutics

KLRA

0.00
  • Kailera Therapeutics announced 2 clinical data poster presentations on ribupatide, its dual GLP-1/GIP agonist program for obesity and overweight, scheduled for June 5-8, 2026 at American Diabetes Association 86th Scientific Sessions in New Orleans.
  • Results have not yet been presented; Kailera plans to show Phase 1 bridging study data for injectable ribupatide on June 8.
  • Study readout supported initiation of Kailera ongoing global Phase 3 KaiNETIC clinical program, positioning injectable ribupatide as lead near-term value driver in its obesity pipeline.
  • Partner Hengrui Pharma will also present Phase 2 results for oral ribupatide on June 7, expanding optionality across oral and injectable formats without disclosing outcomes in this announcement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kailera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130730PRIMZONEFULLFEED9719090) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.